Noida: Yamuna Expressway Industrial Development Authority (YEIDA) has issued a letter of intent (LoI) to Shukra Pharmaceuticals for setting up an advanced medical technologies manufacturing plant spanning 10 acres in the Medical Devices Park in Sector 28 under Invest UP initiative. The company proposes to invest Rs 587 crore on the project.According to officials, a key component of the project will be the production of Boron Neutron Capture Therapy,which is regarded as one of the most advanced treatment options for complex cancer cases.The project is expected to generate over 900 direct and around 2,000 indirect jobs across manufacturing, research and development, quality control, regulatory affairs, sales, and allied services. Officials said the facility will focus on local hiring and skill development, helping reduce import dependence and improve access to affordable, world-class medical devices.The proposed facility will also manufacture a wide range of radiology and imaging equipment, including CT scanners, MRI systems, PET scanners, X-ray machines, and ultrasound devices. In addition, the company planned to produce anaesthesia systems and respiratory care solutions for use in intensive care units and operating theatres.Cardiac implants such as heart valves, stents, and left ventricular assist devices (LVADs) will also be produced at the park to support the treatment of critical heart conditions. The project will further include the manufacture of ventilators and oxygen concentrators to strengthen respiratory care infrastructure.Another major focus area will be medical robotics. The facility will develop soft-tissue surgical robots, orthopaedic robotic systems, dental robotic systems, and neuro-spine robotic platforms aimed at improving surgical precision. The company also plans to manufacture in-vitro diagnostic solutions, including point-of-care testing devices and advanced analysers, to enable faster and more accurate diagnosis.Medical simulators for training doctors, nurses, and paramedical staff will also be set up to enhance clinical skills and reduce patient risk.The LoI was handed over on Tuesday in the presence of YEIDA CEO Rakesh Kumar Singh, additional CEO Shailendra Bhatia, and senior officials of Shukra Pharmaceuticals, including group CEO and global head Dr Minakshi Late, chief operating officer Gaurav Shokeen, vice-president Anil Kumar Verma, and business unit head Kamini Bharti.The Medical Devices Park, spread across over 350 acres along the Yamuna Expressway, is around 80% complete and targeted for full completion by the end of 2026. The park has already received investment commitments exceeding Rs 1,200 crore, with strong industry response to land allotment schemes. Land has so far been allotted to 101 companies.
